drugset / Trial / NCT03154983
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Phase 2
Unknown
48 enrolled
Zhou Fuxiang
Hanchuan City people's Hospital · collabHuangshi Central Hospital · collabHubei Cancer Hospital · collabTaihe Hospital · collabThe Central Hospital of Huanggang · collabThe first hospital of Zaoyang · collabTianmen People's Hospital · collabXianning Central Hospital · collabYangxin People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate Tablets combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer.
Timeline
- Start
- 2017-05-20
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Tegafur | Unknown | 40 mg | Oral |
| Subject | Tegafur | Unknown | 50 mg | Oral |
| Subject | Tegafur | Unknown | 60 mg | Oral |